Results 191 to 200 of about 28,773 (290)

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Evaluating and leveraging large language models in clinical pharmacology and therapeutics assessment: From exam takers to exam shapers

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims In medical education, the ability of large language models (LLMs) to match human performance raises questions about their potential as educational tools. This study evaluates LLMs' performance on Clinical Pharmacology and Therapeutics (CPT) exams, comparing their results to medical students and exploring their ability to identify poorly formulated
Alexandre O. Gérard   +11 more
wiley   +1 more source

Prescription use of acetaminophen among pregnant women in Denmark from 2000 to 2023: A drug utilization study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study was to describe prescription use of acetaminophen, a widely used analgesic and antipyretic generally considered safe during pregnancy, among pregnant women from 2000 to 2023 in Denmark with special attention towards variations following the change in over‐the‐counter (OTC) availability in 2013.
Erika B. Gram   +4 more
wiley   +1 more source

Longitudinal policy surveillance of state obesity legislation in California, 1999-2020. [PDF]

open access: yesBMC Public Health
Payán DD   +3 more
europepmc   +1 more source

Evaluation of the Medicines and Healthcare products Regulatory Agency's introduction of a risk‐proportionate approach for clinical trials: An analysis of 4617 applications assessed between September 2023 and August 2024

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The Medicines and Healthcare products Regulatory Agency (MHRA) introduced a risk‐proportionate approach to assess clinical trial applications for authorisation in August 2023. This study evaluates the impact of this approach on the timelines for reviewing proposals.
Andrea Manfrin   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy